1stOncology™: Cancer Intelligence Service – Page 137 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Immatics Announces $150 Million Underwritten Offering

On August 25, 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, reported that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $150 million. The offering is expected to close on August 26, 2026, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,589,184 additional shares at the public offering price, less the underwriting discount.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering.

A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on April 3, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from:

Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 821-7388, email: [email protected];
Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: [email protected];
Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, email: [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

(Press release, Immatics, AUG 25, 2026, View Source [SID1234670336])

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

On August 25, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, reported to have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections. Human studies showed that the TGF-β trap and IL-15 fusion promoted expansion of progenitor CD8+ T cells and Natural Killer ("NK") cells, provided clinical benefit, and was well tolerated in cancer patients. In addition, the fusion demonstrated activity against HIV-1 and bronchopulmonary dysplasia in highly stringent, relevant animal models. Several publications in leading scientific journals include extensive human and animal study data regarding the TGF-β trap and IL-15 fusion (see References below).

The Company has incorporated these ground-breaking discoveries into its second-generation T Cell Engager ("TCE") and Immune Checkpoint Inhibitor ("ICI") programs, created with its TRBC drug development platform, to strengthen anti-tumor activity and help address the effects of senescent cell accumulation. Its lead product candidate in the TCE Program, HCW11-018b, combines a TGF-β trap and IL-15 fusion with a tissue-factor-targeting BiTE (Bispecific T-cell Engager). This design provides IL-15-driven immune stimulation while using the TGF-β trap to counter immunosuppression and poor T-cell infiltration in solid tumors. HCW11-040, lead candidate of the Company’s second-generation ICI program, is a unique combination of pembrolizumab, a generic form of Keytruda, and the added-on TGF-β/IL-15 moiety, which has demonstrated superior immune-cell activation, expansion, tumor infiltration, and cytotoxicity against cancer cells and tumors compared with pembrolizumab in in-vitro and in-vivo preclinical studies. Both molecules are at IND-enabling stage, and the Company plans to initiate clinical studies in 2027.

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, "HCW Biologics is the leader in creation of multi-valent immunotherapeutics with a unique protein-based scaffold, without the antibody Fc domain. By leveraging our ground-breaking discovery of the novel properties of the TGF-β/IL-15 fusion moiety and incorporating it into our second-generation fusion molecules, we have demonstrated enhanced therapeutic activity over traditional immune checkpoint inhibitor- and BiTE-based approaches. We believe our novel multi-valent immunotherapeutics could revolutionize the immunotherapy field, especially against cancers and senescence-associated dysplasia."

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB.

(Press release, HCW Biologics, AUG 25, 2026, View Source [SID1234670335])

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

On August 25, 2026 Beyond Air, Inc. (NASDAQ: XAIR) reported that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd ("UNIVO") Univo Pharmaceutical Industries Ltd. ("UNIVO"), a public company whose shares are listed for trading on the Tel Aviv Stock Exchange (TASE:UNVO), will acquire control over the outstanding shares of NeuroNOS Israel Ltd. ("NeuroNOS"), a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology. The transaction is intended to provide NeuroNOS with dedicated resources, funding and strategic focus to advance its pipeline candidates targeting complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers including Glioblastoma (GBM), and Alzheimer’s disease.

Currently, Beyond Air, through its wholly owned Irish subsidiary, NeuroNOS Limited, holds 5,000,000 ordinary shares of NeuroNOS, representing approximately 58% of NeuroNOS’s issued share capital on a fully diluted basis. Upon closing, UNIVO will purchase NeuroNOS Limited’s entire stake in NeuroNOS pursuant to a share purchase agreement among Beyond Air, NeuroNOS Limited and UNIVO. In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO’s issued and outstanding share capital, together with warrants to purchase additional UNIVO ordinary shares representing 19.99% of UNIVO’s total outstanding options, warrants and other awards, exercisable at $0.01 per share for five years following closing.

Separately, under an intellectual property transfer agreement between Beyond Air and NeuroNOS Beyond Air will transfer to NeuroNOS certain intellectual property rights and other assets relating to NeuroNOS’s development programs, in consideration for development and commercial milestone payments up to $6.5 million in cash development milestone payments tied to the clinical advancement, regulatory approval and commercialization of a therapeutic product based on NeuroNOS intellectual property. Beyond Air will also be eligible to receive up to $26.0 million in additional commercial milestone payments upon achievement of specified net sales thresholds.

"This transaction marks an important next chapter for NeuroNOS and reflects our confidence in the science and the potential of its pipeline. By combining NeuroNOS with UNIVO, we are creating a more focused path to advance the company’s programs with dedicated resources, while allowing Beyond Air to remain focused on the continued growth and execution of our core LungFit business. We are proud of what has been built at NeuroNOS and look forward to remaining aligned with its progress as a UNIVO shareholder and long-term partner," said Robert Goodman, Chief Executive Officer of Beyond Air.

The transaction is expected to close following satisfaction of the conditions set forth in the definitive agreement, including applicable board and shareholder approvals, regulatory and stock exchange approvals, completion of the contemplated investment and other customary closing conditions.

(Press release, Beyond Air, AUG 25, 2026, View Source [SID1234670334])

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

On August 25, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the journal Cancer Chemotherapy and Pharmacology.

The data shows that TAMP (Trans-Arterial Micro-Perfusion)-mediated delivery concentrated chemotherapy at the tumor site, extracting roughly 51% of the drug locally before it entered the bloodstream, meaningfully lowering systemic exposure in a way that could reduce systemic side effects. In addition, a statistically significant correlation between the drug’s local metabolism and a drop in the CA 19-9 tumor marker provided an early indication of improved drug penetration into the tumor area and potential tumor response with intra-arterial delivery.

RenovoRx also recently announced the closing of enrollment of the TIGeR-PaC trial, with trial completion expected in the first half of 2027 and expected initial top line data availability in the second half of 2027.

"The findings from this PK/PD study provide additional meaningful mechanistic support for our TAMP platform’s targeted drug-delivery approach," said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. "The results provide direct pharmacokinetic evidence supporting TAMP’s potential to deliver chemotherapy more selectively to the tumor while limiting systemic exposure. These findings strengthen TAMP, enabled by our RenovoCath device, as a differentiated approach to improving the therapeutic index of chemotherapy in patients with LAPC."

The PK/PD study, titled "Pharmacokinetic and Pharmacodynamic Sub-study of Trans-arterial vs Intravenous Gemcitabine in the TIGeR-PaC Phase 3 Clinical Trial," compared the systemic drug levels of intra-arterial gemcitabine (IAG) delivered via TAMP using RenovoCath against standard intravenous gemcitabine (IVG) delivered systemically in 16 patients with LAPC across six clinical sites (11 patients received IAG; 5 received IVG). Funding for this study was provided by RenovoRx.

Key Findings:

Reduced systemic exposure: IAG resulted in significantly lower total systemic gemcitabine exposure compared to IVG, despite being administered at a 50% higher infusion concentration rate, supporting the potential of TAMP to concentrate therapy at the intended treatment site while limiting systemic exposure.
Substantial local drug extraction: A targeted extraction ratio of 0.511 was observed (derived from a bioavailability estimate of 0.489), indicating approximately 51% of the intra-arterially delivered gemcitabine was extracted at the site of intra-arterial delivery before entering systemic circulation. This finding provides direct pharmacokinetic evidence supporting the targeted drug-delivery mechanism underlying the TAMP platform.
Tumor marker response: A statistically significant correlation was observed between higher systemic levels of dFdU and greater reductions in CA 19-9 tumor marker levels following IAG treatment (Pearson’s r = -0.75; P = 0.034; based on eight evaluable patients, with three excluded for normal baseline CA 19-9). dFdU is gemcitabine’s inactive metabolite, and higher dFdU levels are consistent with rapid local uptake and metabolism of gemcitabine at the treatment site, providing an initial pharmacodynamic signal linking drug exposure with a biomarker of tumor response.
Consistent delivery across arterial sites: No statistically significant differences in gemcitabine or dFdU pharmacokinetic parameters were observed based on IAG delivery site, whether administered via the superior mesenteric artery or the celiac artery.

The Company believes this data provides evidence that IAG delivery via the TAMP therapy platform achieves meaningful local drug extraction while reducing systemic gemcitabine exposure, supporting RenovoRx’s differentiated approach to targeted intra-arterial chemotherapy in patients with LAPC.

Publication Details
Title: Pharmacokinetic and Pharmacodynamic Sub-study of Trans-arterial vs Intravenous Gemcitabine in the TIGeR-PaC Phase 3 Clinical Trial
Journal: Cancer Chemotherapy and Pharmacology
DOI: 10.1007/s00280-026-04939-0

(Press release, Renovorx, AUG 25, 2026, View Source [SID1234670333])

Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Data Model, Enabling Precision Medicine Research at Unprecedented Scale

On August 25, 2026 Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, reported the expansion of its non-small cell lung cancer (NSCLC) Panoramic dataset with a comprehensive biomarker data model, delivering specimen-level molecular detail at a scale of 345,000+ patients across early and advanced settings. This expansion enables researchers to more deeply explore biomarker-driven treatment patterns, patient outcomes and evolving testing practices across the NSCLC care journey.

The expanded biomarker data model delivers richer molecular profiling across the full spectrum of guideline-recommended biomarkers—including EGFR, BRAF, KRAS, ALK, ROS1, RET, MET, HER2/ERBB2, NTRK, and PD-L1. Each biomarker now includes specimen-level data elements (collection date, received date, test type, lab name, and mutation/alteration detail where applicable), enabling researchers to understand not just what biomarkers are present, but how and when they were tested for all testing instances. In addition to expanding depth on standard of care testing, the dataset also captures emerging biomarkers like KEAP1, STK11, TP53, MTAP, CDKN2A, HRAS, NRAS, and PIK3CA that are increasingly being studied as predictors of immunotherapy response and resistance, with the flexibility to incorporate additional emerging biomarkers as research and customer needs evolve.

"For biopharma partners developing precision therapies in lung cancer, real-world biomarker data with depth, granularity, and scale is absolutely necessary to answer their most complex research questions," said Kate Estep, Chief Product Officer at Flatiron Health. "This expansion delivers the biomarker detail our partners need—from established drivers to emerging targets—within a single, rigorously validated dataset spanning more than 345,000 patients."

The NSCLC Panoramic dataset enables research that has historically been difficult at scale, including biomarker prevalence studies in rare mutation-defined cohorts, treatment sequencing post-targeted therapy, resistance mechanism analysis, and real-world comparator arm development. Flatiron’s lung cancer research portfolio demonstrates the breadth of applications enabled by the dataset—from machine learning risk stratification in PD-L1-high patients to real-world response assessment and digital twin counterfactual modeling.

"Biomarker-directed therapy has transformed lung cancer care, and meaningful studies of treatment patterns, outcomes, and resistance require data with both the clinical depth to capture how a patient’s disease evolves and the scale to generate robust insights across diverse populations," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "This expanded data model reflects the true complexity of modern lung cancer care, capturing not just whether a biomarker is present, but the specimen-level detail and temporal detail that enables meaningful, regulator-grade evidence."

Flatiron’s lung cancer real-world evidence has supported diverse research applications, including:

Real-world response assessment and subsequent treatment outcomes in advanced/metastatic NSCLC
Machine learning risk stratification to identify PD-L1-high subgroups benefiting from chemotherapy + pembrolizumab
External validation of deep learning biomarkers for IO outcomes prediction
Risk stratification in patients with multiple organ metastases
Regression discontinuity methods strengthening causal inference in lung cancer RWE
Digital twin models for patient-level counterfactual prediction
In addition to multiple biotech organizations, more than 70% of leading biopharma companies use Flatiron’s NSCLC Panoramic datasets for its combination of scale, depth, and granularity, including specimen-level biomarker data across more than 345,000 patients in early and advanced disease settings. Flatiron’s lung cancer portfolio also includes more than 28,000 patients with small cell lung cancer, providing complementary real-world evidence across the full spectrum of thoracic malignancies and enabling more rigorous research into testing patterns, treatment decisions, and patient outcomes. Learn more about the company’s presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

(Press release, Flatiron Health, AUG 25, 2026, View Source [SID1234670331])